Advertisement

Intravenous Therapies for Intractable Headache

  • Magdalena AnitescuEmail author
Chapter

Abstract

Unrelenting, severe headaches are difficult to treat since they usually do not respond to conventional medical management. Among invasive interventions, infusion therapies have emerged as an effective treatment for refractory headaches when other noninvasive treatments have been exhausted. This chapter reviews several pharmacological options of intravenous infusions for intractable headaches.

Keywords

Trigeminal Neuralgia Complex Regional Pain Syndrome Ergot Alkaloid Medication Overuse Headache Reversible Cerebral Vasoconstriction Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol. 2008;7:354–61.PubMedCrossRefGoogle Scholar
  2. 2.
  3. 3.
    Olsen J. The international classification of headache disorders. Headache. 2008;48:691–3.CrossRefGoogle Scholar
  4. 4.
    American Headache Society. Refractory headache special section, meeting minutes. 2006. Available from: http://www.americanheadachesociety.org/assets/1/7/Refractory_Headache_Section_Minutes_6-23-06.pdf. 23 June 2006.
  5. 5.
    Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010;50:1499–506.PubMedCrossRefGoogle Scholar
  6. 6.
    Tfelt-Hansen PC, Koehler PJ. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache. 2011;51:752–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Lambert GA. The lack of peripheral pathology in migraine headache. Headache. 2010;50:895–908.PubMedCrossRefGoogle Scholar
  8. 8.
    Stillman MJ. Medical treatment of chronic daily headaches: chronic migraine, chronic tension-type headaches, new daily persistent headaches, hemicrania continua, and medication overuse headache. In: Tepper SJ, Tepper DE, editors. The Cleveland clinic manual of headache therapy. New York: Springer Science; 2011. p. 167–81.CrossRefGoogle Scholar
  9. 9.
    Sarchielli P, Di Filippo M, Nardi K, Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep. 2007;11:343–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Kelley NE, Tepper DE. Rescue therapy for acute migraine, Part 1: triptans, dihydroergotamine, and magnesium. Headache. 2012;52:114–28.PubMedCrossRefGoogle Scholar
  11. 11.
    Charles JA, von Dohln P. Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine. Headache. 2010;50:852–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Gelfand AA, Goadsby PJ. A neurologist’s guide to acute migraine therapy in the emergency room. Neurohospitalist. 2012;2:51–9.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Silberstein SD, Elliott A, et al. Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30:334–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Ford RG, Ford KT. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Headache. 1997;37:129–36.PubMedCrossRefGoogle Scholar
  16. 16.
    Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache. 1994;34:578–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Kabouche MA, Qureshi FA, Lewis DW. Headache in the pediatric emergency department. Headache in Children and Adolescents. BC Decker Inc. 2008;49:106–9.Google Scholar
  18. 18.
    Stillman MH, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache. 2004;44:65–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Krusz JC. Intravenous treatment of chronic daily headaches in the outpatient headache clinic. Curr Pain Headache Rep. 2006;10:47–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate vs intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache. 2001;41:976–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Shahien R, Saleh SA, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand. 2011;123:257–65.PubMedCrossRefGoogle Scholar
  22. 22.
    Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996;36:265.CrossRefGoogle Scholar
  23. 23.
    Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002;42:519–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Mauskop A, Varughese J. Why all migraine patients should be treated with magnesium. J Neural Transm. 2012;119:575–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Wang F, Van Den Eeden SK, Ackerson LM, et al. Oral magnesium oxide prophylaxis of frequent migraine headache in children: a randomized, double-blind, placebo-controlled trial. Headache. 2003;43:601–10.PubMedCrossRefGoogle Scholar
  26. 26.
    Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache. 1996;36:154–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Demirkaya S, Vural O, Dora B, Topcuoglu MA. Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache. 2001;41:171–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Mays MA. Treatment of major secondary headaches. In: Tepper SJ, Tepper DE, editors. The Cleveland clinic manual of headache therapy. New York: Springer Science; 2011. p. 195–208.CrossRefGoogle Scholar
  29. 29.
    Simmonds MK, Rashiq S, Sobolev IA, Dick BD, Gray DP, Stewart BJ, Jamieson-Lega KI. The effect of single-dose propofol injection on pain and quality of life in chronic daily headache: a randomized, double-blind, controlled trial. Anesth Analg. 2009;109:1972–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40:224–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Mendes PM, Silberstein SD, Young WB, Rozen TD, Paolone MF. Intravenous propofol in the treatment of refractory headache. Headache. 2002;42:638–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Marmura M, Rosen N, Abbas M, Silberstein S. Intravenous lidocaine in the treatment of refractory headache: a retrospective case series. Headache. 2009;49:286–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Stillman MJ. Treatment of trigeminal autonomic cephalalgias and other primary headaches. In: Tepper SJ, Tepper DE, editors. The Cleveland clinic manual of headache therapy. New York: Springer Science; 2011. p. 137–50.CrossRefGoogle Scholar
  34. 34.
    Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia. 2003;23:963–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Marmura MJ. Intravenous lidocaine and mexiletine in the management of trigeminal autonomic cephalalgias. Curr Pain Headache Rep. 2010;14:145–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Fanaee E, Anitescu M, Patil SK. Sustained pain relief after lidocaine infusions for chronic pain syndromes: a retrospective analysis. ASA. 2010;A301. http://education.asahq.org/sites/production.asahq-dev.org/files/a301.pdf.
  37. 37.
    Patil SK, Anitescu M. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5 year retrospective analysis. Pain Med. 2012;13:263–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Flexman AM, Ng JL, Gelb AW. Acute and chronic pain following craniotomy. Curr Opin Anaesthesiol. 2010;23:551–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Bar-Joseph G, Guilburd Y, Tamir A, Guilburd JN. Effectiveness of ketamine in decreasing intracranial pressure in children with intracranial hypertension. J Neurosurg Pediatr. 2009;4:40–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Schwedt TJ, Silberstein SD. 14th international headache congress: clinical highlights. Headache: the Journal of Head and Face Pain. 2010;50(3):509–19.Google Scholar
  41. 41.
    Krusz JC, Cagle J, Scott-Krusz VB. Ketamine for treating multiple types of headaches (abstract). Cephalalgia. 2009;29 Suppl 1:151–2.Google Scholar
  42. 42.
    Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 2002;39:215–22.PubMedCrossRefGoogle Scholar
  43. 43.
    Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines and others. Headache. 2012;52:292–306.PubMedCrossRefGoogle Scholar
  44. 44.
    Kriegler JS. Acute treatment of episodic migraine. In: Tepper SJ, Tepper DE, editors. The Cleveland clinic manual of headache therapy. New York: Springer Science; 2011. p. 107–19.CrossRefGoogle Scholar
  45. 45.
    Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011;83:271–80.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Anesthesia and Critical CareUniversity of Chicago Medical CenterChicagoUSA

Personalised recommendations